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Abstract 
 
Objectives: To describe the trajectory of radiographic progression amongst patients 
with psoriatic arthritis (PsA) who transitioned from conventional synthetic disease 
modifying drugs (csDMARDs) to anti-tumour necrosis factor alpha inhibitors (anti-
TNF) in routine care.   
 
Methods: A retrospective sample of patients with PsA (CASPAR criteria) was taken 
from the Bath longitudinal cohort. All patients had radiographs of the hands and feet 
taken: five years before [T0], at the time of [T1] and five years post [T2] commencing 
anti-TNF treatment. Radiographs were scored blinded using the PsA-modified 
Sharp-van der Heijde score (mSvdHS)  and for osteoproliferation (PARS) by AA, AA 
and WT. This sample size was calculated to ensure 90% power to determine the 
smallest detectable difference of the mSvdHS to a 5% significance level. Cumulative 
probability plots were used to determine the probability of radiographic progression 
pre- (T0-T1) and post- (T1-T2) anti-TNF treatment.  
 
Results: Eighty four radiographs from twenty eight patients were selected for 
inclusion. The median (IQR) disease duration at baseline (T0) was 8.5 (0-19.5) 
years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years 
(4.25-5.87) respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-
27.5). The median (IQR) rate of change in mSvdHS per year reduced after 
commencing anti-TNF from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) 
between T1-T2 (p=0.012). 
 
Conclusion: The trajectory of damage accumulation over a 10 year period in this 
observational clinical cohort is low overall. The rate of radiographic damage as 
measured by the mSvdHS slows following commencement of anti-TNF.   
(249/250 words) 
 
Key message: Radiographic progression slows in patients escalated from 
csDMARD to anti-TNF therapy in this long-term study.  (15/15 words) 
 
 
Background:  
 
Plain radiography and the quantification of radiographic damage is an important 
outcome in psoriatic arthritis (PsA) from the patient and clinician perspective. 
Patients rank the prevention of damage as a high priority from treatment1. Clinicians 
recognise that the tight control of disease with early intervention and a treat to target 
approach in rheumatoid arthritis has led to less damage accumulation and improved 
physical function in established disease2. Data are emerging that a similar approach 
may improve outcome in PsA3,4. 
Previous perceptions of PsA as a relatively mild arthropathy have been succeeded 
by observational studies describing the prevalence and progression of radiographic 
damage over time. In an observational study of 129 patients with early PsA, 27% 
were found to have erosive disease at baseline and 47% had erosive disease at 2 
years of follow-up5. In a cohort of 71 patients with no erosive disease at baseline, 
45% developed erosions over an average follow-up period of 8 years6.  
 
Whilst the slowing of long-term radiographic progression with anti-TNF treatment has 
been demonstrated in rheumatoid arthritis and in randomised clinical trials in PsA, 
there is little long term follow-up data from observational PsA cohorts using formal 
validation scoring systems such as the modified Sharp/van der Heijde score 
(mSvdHS)4,7,8. Real world evidence is especially important in the field of PsA 
because the disease phenotype included in drug development trials are increasingly 
homogenous, representing predominantly polyarticular disease and under 
representing the oligo and monoarticular phenotypes9. Radiographic progression can 
be slow in PsA and the duration of randomised controlled trials (RCT) short, even in 
the extension studies; therefore there is a lack of meaningful long term follow up data 
in what is a lifelong disease.  
 
We aimed to quantify the rate of radiographic progression amongst patients with PsA 
who transitioned from conventional synthetic disease modifying anti-rheumatic drugs 
(csDMARDs) to anti-tumour necrosis factor alpha (anti-TNF) therapy in routine care. 
 
 
Materials and Methods:  
 
Cohort selection 
A retrospective convenience sample of 28 patients fulfilling the CASPAR criteria for 
PsA was taken from the Bath longitudinal cohort. Patients have clinical, patient 
reported and radiographic assessments as part of routine care. All patients at entry 
to the cohort have baseline hand and feet radiographs. All patients requiring biologic 
disease modifying anti-rheumatic drugs (bDMARD) have the same data collected as 
part of a protocol at every visit, including radiographs every two years. Baseline 
demographics and measures of disease activity at commencement of anti-TNF 
therapy and at follow-up, including tender joint count (TJC), swollen joint count 
(SJC), psoriasis area and severity index (PASI), Stanford Health Assessment 
Questionnaire Disability Index (HAQ) scores and C-reactive protein (CRP) are 
reported using descriptive statistics. We included all patients who had antero-
posterior radiographs of the hands and feet taken at three time points; five years 
before [T0], at the time of [T1] and five years after [T2] commencing anti-TNF 
treatment. This sample size was calculated to ensure 90% power to determine the 
smallest detectable difference of the mSvdHS (6.25 units) to a 5% significance level.  
 
Radiographic Scoring methods 
Radiographs were scored for erosions and joint space narrowing by three assessors 
(AA, AA and WT) using the modified Sharp/van der Heijde score (mSvdHS), which 
has been found to be the method that is most sensitive to change in PsA. 
Proliferation was also scored using the Psoriatic Arthritis Ratingen Score (PARS) 
method10. The technical details on radiograph acquisition and viewing have been 
previously reported11. The assessors were blinded to patient identifiers, 
demographics, treatment and chronological order of the radiographs. Reliability was 
assessed using inter-class correlation coefficient (ICC). Inter-rater reliability was 
assessed using a sample of nine sets of radiographs scored by all three assessors 
and intra-rater reliability was assessed with individual assessors scoring the same 
nine radiographs three weeks after the initial inter-rater reliability exercise. The rate 
of radiographic progression (units per year) was calculated for the individual 
components of radiographic damage by dividing the change of the individual scores 
over the duration of time between the radiographs at T0-T1 and T1-T2 for each 
patient. 
 
Statistical analysis 
All statistical analysis was performed using SPSS-23 (IBM Corp.). Inter-rater 
reliability was assessed using ICC. The significance of changes in clinical outcomes 
between time points was assessed using the Wilcoxon Signed-Rank test. 
Cumulative probability plots were used to illustrate radiographic progression pre- (T0 
to T1) and post- (T1 to T2) anti-TNF treatment. The two-sample Kolmogorov-Smirnov 
test (K-S test) was used to determine if there was a significant change in the rate of 
progression following the commencement of anti-TNF therapy.  
 
Ethics 
This study has been conducted according to the principles in the Declaration of 
Helsinki and was approved by the Bath Research Ethics Committee. Informed 
written consent was obtained from all participants. 
 
Results:  
 
Twenty eight patients were identified for inclusion: 15 were male, the mean (±SD) 
age was 61 years (±13.4) and median (IQR) disease duration at T0 was 8.5 years 
(0.00-19.50). The median (IQR) study follow up period was 9.5 years (8.00-12.00). 
Inter-rater and intra-rater ICCs were >0.9 for the total mSvdHS and its sub-scores. 
Clinical outcomes at initiation of anti-TNF (T1) are reported in Table 1.  
 
Clinical Outcomes T1 – T2 
The median (IQR) TJC, SJC, PASI and HAQ showed statistically significant 
improvements between T1 to T2 as assessed by the Wilcoxon signed-rank test. The 
median (IQR) TJC improved from 23 (13.5-34.0) to 6 (0.5-17.0; p<0.0001), the 
median (IQR) SJC improved from 7 (4.0-10.8) to 0 (0.0-3.5; p<0.0001), the median 
PASI improved from 0.8 (0.30-1.85) to 0.3 (0.00-0.70; p=0.03) and the median HAQ 
improved from 1.3 (0.94-2.09) to 1.1 (0.25-1.84; p=0.01). 
 
Radiographic progression prior to anti-TNF (T0 – T1) 
Radiographic progression on csDMARDs (T0 – T1) occurred in 89% (n=25) of 
patients, with progression in erosions and joint space narrowing occurring in 61% 
(n=17) and 86% (n=24) of patients respectively.  The median mSvdHS at T0 was 8.5 
(IQR 1.75-30.50). The median scores for erosions and joint space narrowing were 
1.5 (IQR 0.00-11.50) and 4.5 (IQR 1.00-15.00) respectively.  The median (IQR) rate 
of progression in mSvdHS, erosion score and joint space narrowing score per year 
was 2.1 (0.88-3.93), 0.4 (0.00-1.91), and 1.4 (0.68-2.30) respectively. 
 
Radiographic progression following anti-TNF treatment (T1 – T2) 
64% of patients continued to progress radiographically following anti-TNF treatment, 
with 32% developing progressive erosive disease and 61% developing progressive 
joint space narrowing.  The median (IQR) rate of change in mSvdHS per year 
improved to 1.0 (0.05-2.35) units/year on anti-TNF (p=0.01) (Figure 1). The median 
(IQR) rate of change of erosions improved to 0.0 units/year (0.00-0.81) and the 
median rate of joint space narrowing improved to 0.7 (0.05-1.81) but these values 
did not reach statistical significance. 
 
Rate of progression of proliferative change pre and post anti-TNF treatment (T1 – T2) 
The median (IQR) rate of proliferation numerically reduced from 0.38 units/year  
(-0.30-1.64) to 0.00 units/year (-0.25-0.79) post initiation of anti-TNF, but the 2 
sample KS test shows no significant difference between the two groups (p=0.346); 
figure 2. 
 
Discussion:  
 
This study demonstrates evidence of reduced rate of radiographic progression as 
measured by the mSvdHS amongst patients commenced on anti-TNF therapy in an 
observational clinical cohort of patients with PsA.  
 
The effect of anti-TNF on radiographic progression in PsA was first reported in a 
placebo-controlled RCT involving etancercept, in which the modified Sharp Score 
(mTSS) was used to score radiographs after the initial 24 week blinded stage and 
after the 48 week extension. Radiographic progression was inhibited at 12 months in 
the etanercept group (0.03 units) compared to a deterioration in the placebo group 
(1.00 unit; p=0.0001)12. Subsequent placebo-controlled RCTs involving infliximab, 
adalimumab, golimumab, certolizumab, ustekinumab and secukinumab, have also 
demonstrated an improvement in the rate of radiographic progression in the first 24 
weeks of treatment, with a higher proportion of non-progressors in the bDMARD 
arms7,13,14,15,16,17. More recently, the GO-REVEAL study has published its five year 
follow up data suggesting that reduction in radiographic progression is preserved 
through five years of treatment with golimumab18.  
 
Ravindran et al reported progression of damage amongst 139 patients over a five 
year period using the modified Sharp Score (mSS). The study demonstrated the 
ability of the mSS to detect correlations between damage and physical function 
measured with the HAQ at baseline (r=0.29) and follow-up (r=0.48)19. A report from 
the Swedish early PsA registry evaluated progression of 72 patients with early PsA 
over the first five years of disease and noted slow rates of progression20.  
 
To our knowledge our study is the first to describe the rate of radiographic 
progression in a group of patients in the years leading up to and following the 
commencement of an anti-TNF therapy, over a ten year period.  
 
The rate of mSvdHS progression reported in our study provides an estimate of 
radiographic progression over a decade of treatment in the modern era of higher 
dose csDMARD use and widespread adoption of bDMARD use. The overall rate of 
mSvdHS progression in our cohort prior to the commencement of anti-TNF therapy 
was low, but certainly higher than rates of progression reported in the placebo-
controlled RCTs of patients with PsA, perhaps reflecting the clinical-practice 
complexity of a treat-to-target approach in a real-world clinical cohort with 
comorbidities and relative contraindications to a strict treat-to-target approach21. 
 
The participants included in this study are those with active peripheral joint disease 
requiring bDMARD treatment, as evidenced by the median TJC, SJC and CRP of the 
cohort at the time of anti-TNF commencement (Table 1). However the selection of 
patients with a long period of treatment with csDMARDs prior to commencement of 
anti-TNF is a potential source of bias, as this may represent a cohort of patients with 
a milder disease course, in addition to patients in whom escalating to anti-TNF was 
not undertaken for clinical reasons or patient preference. Conversely, it is also worth 
noting that by excluding patients who had incomplete sets of radiographs at the three 
time points, there is the potential for selection bias towards a population of more 
patients who may have more active disease. These caveats are a reflection of the 
heterogeneity of an observational clinical cohort.  
 
We have also demonstrated a slowing of radiographic progression as measured by 
the mSvdHS in a cohort of PsA patients with high disease activity at the time of anti-
TNF commencement, from a median mSvdHS of 2.1 to 1.0 units/year following 
commencement of anti-TNF treatment. This mirrored the improvements in clinical 
outcomes such as tender joint count, swollen joint count, PASI, and HAQ, and likely 
represents improvement in disease activity rather than a drug-specific effect. We 
demonstrate a numerical reduction in the rate of individual features of radiographic 
damage, but this was not statistically significant. This may be a reflection of the small 
sample size of our cohort, chronological blinding in radiograph scoring, or the 
influence of the natural history of disease of the disease over time.  
 
The main consideration when interpreting the results of our study is the relatively 
small cohort size, which does not allow for a meaningful sub-group analysis to look 
at relative progressors versus non-progressors as separate populations. In our 
study, progression in joint space narrowing was responsible for a significant 
proportion of radiographic progression post anti-TNF, which is important to note 
given the lack of specificity of joint space narrowing as a radiographic outcome in 
PsA. The strengths of our study include the pre-determined sample size, long follow-
up period, good inter-rater reliability, and formal blinded radiographic scoring.  
 
Conclusions 
 
We report an estimate of radiographic progression in PsA over a ten year period 
amongst patients with more aggressive disease who have required anti-TNF 
treatment as part of routine care. The trajectory of damage accumulation is low 
overall and the rate of progression in mSvdHS slows amongst patients commenced 
on anti-TNF in this clinical-practice cohort.   
 
(Word count: 2618/3500 – not including abstract/table/graph) 
 
Population characteristics at commencement of anti-TNF (n=28) 
_________________________________________________________________________ 
 
Baseline Demographics: Mean (±SD) or Median (IQR) 
  
Sex:     Male 54 % (15) 
     Female 46% (13) 
 
Age:         61 years (±13.45) 
 
Disease duration at T0:  8.5 years  (0.00-19.50)  
Total disease duration:  18 years          (9.25-29.50)   
Duration of anti TNF treatment: 5.0 years         (4.00-6.00)   
Total study follow-up:   9.5 years         (8.00-12.00)  
 
Anti-TNF Medication: n (%) 
 
Adalimumab    12  (43) 
Etanercept    13  (46) 
Golimumab    3    (11) 
 
Clinical assessment at commencement of anti-TNF: median (IQR) 
 
Tender joint count:   23.0 (13.50-34.00) 
Swollen joint count:   7.0  (4.00-10.80) 
PASI:     0.8  (0.30-1.85) 
HAQ:     1.3  (0.94-2.09) 
CRP:     10.0 (4.25-17.75) 
 
Radiographic assessment at commencement of anti-TNF: median (IQR) 
 
mSvdHS             17.50 (10.25-35.75) 
Rate of Erosions   0.42 (0.00-1.91) 
Rate of Joint Space Narrowing   1.43     (0.68-2.29) 
Rate of mSvdHS   2.09     (0.88-3.92) 
_________________________________________________________________________ 
Table 1: Population characteristics at baseline. 
Key: TNF = tumour necrosis factor; SD = standard deviation; IQR = inter-quartile range; PASI = psoriasis activity severity index; 
HAQ = health assessment questionnaire; mSvdHS = modified Sharp-van der Heijde score. 
Footnote: mean (standard deviation) and median (interquartile ranges have been used throughout as appropriate. 
 
 
 
 
 
 
 
Figure 1: Cumulative probability plot demonstrating an increased rate of radiographic 
progression as calculated by median mSvdHS score in patients on csDMARDs compared 
with anti-TNF treatment. 
Key: mSvdHS = modified Sharp-van der Heijde score; TNF = tumour necrosis factor. 
 
 
 
 
 
Figure 2: Cumulative probability plot demonstrating changes in rate of progression of 
proliferation pre and post TNF inhibition. 
Key: TNF = tumour necrosis factor. 
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